Pressurized intraperitoneal aerosol chemotherapy with cisplatin and doxorubicin or oxaliplatin for peritoneal metastasis from pancreatic adenocarcinoma and cholangiocarcinoma.
PIPAC
aerosol chemotherapy
carcinomatosis
cholangiocarcinoma
locoregional chemotherapy
pancreatic cancer
peritoneal metastases
Journal
Therapeutic advances in medical oncology
ISSN: 1758-8340
Titre abrégé: Ther Adv Med Oncol
Pays: England
ID NLM: 101510808
Informations de publication
Date de publication:
2020
2020
Historique:
received:
09
01
2020
accepted:
15
06
2020
entrez:
13
8
2020
pubmed:
13
8
2020
medline:
13
8
2020
Statut:
epublish
Résumé
Systemic chemotherapy for pancreatic adenocarcinoma (PDAC) and cholangiocarcinoma (CC) with peritoneal metastases (PM) is affected by several pharmacological shortcomings and low clinical efficacy. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is expected to maximize exposure of peritoneal nodules to antiblastic agents. This study aims to evaluate safety and efficacy of PIPAC for PM of PDAC and CC origin. This is a retrospective analysis of consecutive PDAC and CC cases with PM treated with PIPAC at two European referral centers for peritoneal disease. We prospectively recorded from August 2016 to May 2019 demographic, clinical, surgical, and oncological data. We performed a feasibility and safety assessment and an efficacy analysis based on clinical and pathological regression. Twenty patients with PM from PDAC (14) and CC (six) underwent 45 PIPAC administrations. Cisplatin-doxorubicin or oxaliplatin were administered to eight and 12 patients, respectively. We experienced one intraoperative complication (small bowel perforation) and 18 grade 1-2 postoperative adverse events according to Common Terminology Criteria for Adverse Events version 4.0. A pathological regression was recorded in 50% of patients (62% in the cisplatin-doxorubicin cohort and 42% in the oxaliplatin one). Median survival from the first PIPAC was 9.7 and 10.9 months for PDAC and CC, respectively. PIPAC resulted feasible and safe without relevant toxicity issues, with both cisplatin-doxorubicin and oxaliplatin. The pathological response observed supports the evidence of antitumoral activity. Despite the study limitations, these outcomes are encouraging, recommending PIPAC in prospective, controlled trials in the palliative setting or the first line chemotherapy for PM from PDAC and CC.
Sections du résumé
BACKGROUND
BACKGROUND
Systemic chemotherapy for pancreatic adenocarcinoma (PDAC) and cholangiocarcinoma (CC) with peritoneal metastases (PM) is affected by several pharmacological shortcomings and low clinical efficacy. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is expected to maximize exposure of peritoneal nodules to antiblastic agents. This study aims to evaluate safety and efficacy of PIPAC for PM of PDAC and CC origin.
METHODS
METHODS
This is a retrospective analysis of consecutive PDAC and CC cases with PM treated with PIPAC at two European referral centers for peritoneal disease. We prospectively recorded from August 2016 to May 2019 demographic, clinical, surgical, and oncological data. We performed a feasibility and safety assessment and an efficacy analysis based on clinical and pathological regression.
RESULTS
RESULTS
Twenty patients with PM from PDAC (14) and CC (six) underwent 45 PIPAC administrations. Cisplatin-doxorubicin or oxaliplatin were administered to eight and 12 patients, respectively. We experienced one intraoperative complication (small bowel perforation) and 18 grade 1-2 postoperative adverse events according to Common Terminology Criteria for Adverse Events version 4.0. A pathological regression was recorded in 50% of patients (62% in the cisplatin-doxorubicin cohort and 42% in the oxaliplatin one). Median survival from the first PIPAC was 9.7 and 10.9 months for PDAC and CC, respectively.
CONCLUSION
CONCLUSIONS
PIPAC resulted feasible and safe without relevant toxicity issues, with both cisplatin-doxorubicin and oxaliplatin. The pathological response observed supports the evidence of antitumoral activity. Despite the study limitations, these outcomes are encouraging, recommending PIPAC in prospective, controlled trials in the palliative setting or the first line chemotherapy for PM from PDAC and CC.
Identifiants
pubmed: 32782488
doi: 10.1177/1758835920940887
pii: 10.1177_1758835920940887
pmc: PMC7383654
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1758835920940887Informations de copyright
© The Author(s), 2020.
Déclaration de conflit d'intérêts
Conflict of interest statement: The authors declare that there is no conflict of interest.
Références
Pleura Peritoneum. 2019 Jun 27;4(2):20190010
pubmed: 31417958
Pleura Peritoneum. 2018 Sep 25;3(3):20180114
pubmed: 30911662
Invest New Drugs. 2019 Jun;37(3):415-423
pubmed: 30019100
Invest New Drugs. 2016 Oct;34(5):636-42
pubmed: 27339809
J Chemother. 2014 Aug;26(4):243-7
pubmed: 24070164
Colorectal Dis. 2016 Apr;18(4):364-71
pubmed: 26400556
Pleura Peritoneum. 2018 Jun 08;3(2):20180113
pubmed: 30911658
Ann Oncol. 2015 Sep;26 Suppl 5:v56-68
pubmed: 26314780
Gastroenterology. 2005 May;128(6):1606-25
pubmed: 15887154
Cancer Med. 2014 Dec;3(6):1502-11
pubmed: 25111859
Gynecol Oncol. 2018 Jul;150(1):23-30
pubmed: 29743140
Ann Surg Oncol. 2013 Oct;20(11):3504-11
pubmed: 23765417
Lancet. 2014 Jun 21;383(9935):2168-79
pubmed: 24581682
Br J Surg. 2017 May;104(6):669-678
pubmed: 28407227
J Clin Oncol. 2013 Jan 1;31(1):23-9
pubmed: 23213101
Minerva Med. 2019 Aug;110(4):385-398
pubmed: 31081306
Clin Exp Metastasis. 2017 Jun;34(5):291-293
pubmed: 28593512
Anticancer Res. 2018 Jan;38(1):373-378
pubmed: 29277797
Science. 2009 Jun 12;324(5933):1457-61
pubmed: 19460966
Clin Exp Metastasis. 2017 Jun;34(5):309-314
pubmed: 28516306
N Engl J Med. 2011 May 12;364(19):1817-25
pubmed: 21561347
Ann Oncol. 2014 Aug;25(8):1650-6
pubmed: 24759568
Langenbecks Arch Surg. 2005 Apr;390(2):94-103
pubmed: 15578211
Eur J Surg Oncol. 2009 Jun;35(6):600-4
pubmed: 19131205
Eur J Surg Oncol. 2019 Dec;45(12):2386-2391
pubmed: 31092362
PLoS One. 2017 Oct 19;12(10):e0186709
pubmed: 29049340
Lancet Oncol. 2019 Jul;20(7):e368-e377
pubmed: 31267971
Gut. 2012 Dec;61(12):1657-69
pubmed: 22895392
J Clin Oncol. 2014 Aug 10;32(23):2423-9
pubmed: 24982456
Future Oncol. 2010 Oct;6(10):1625-41
pubmed: 21062160
Histopathology. 2019 Jun;74(7):1014-1024
pubmed: 30687944
Oncologist. 2015 Feb;20(2):143-50
pubmed: 25582141
BJS Open. 2020 Apr;4(2):206-215
pubmed: 31957257
Eur J Surg Oncol. 2017 Jun;43(6):1102-1109
pubmed: 28431896
J Gastrointest Surg. 2000 Nov-Dec;4(6):567-79
pubmed: 11307091
Eur J Cancer. 2015 Oct;51(15):2169-2178
pubmed: 26421820
Pleura Peritoneum. 2016 Jun 1;1(2):99-107
pubmed: 30911613
World J Gastroenterol. 2015 Jan 7;21(1):262-8
pubmed: 25574100
Clin Exp Metastasis. 2018 Oct;35(7):635-640
pubmed: 30062506
Abdom Imaging. 2013 Dec;38(6):1422-30
pubmed: 23744439
Eur J Surg Oncol. 2018 Jul;44(7):1112-1117
pubmed: 29753612
Cancer Chemother Pharmacol. 2019 Mar;83(3):425-430
pubmed: 30511218
Ann Surg Oncol. 2013 Jul;20(7):2311-6
pubmed: 23377563
Crit Rev Oncol Hematol. 2009 Mar;69(3):259-70
pubmed: 18977670